Literature DB >> 15564258

Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab.

Andrew J K Ostor1, Adrian J Crisp, Margaret F Somerville, David G I Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15564258      PMCID： PMC534441          DOI： 10.1136/bmj.329.7477.1266

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].

Authors:  I Dotan; D Yeshurun; A Hallak; N Horowitz; E Tiomny; S Reif; Z Halpern; D Rachmilewitz
Journal:  Harefuah       Date:  2001-04

2.  Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis.

Authors:  Phillip A Courtney; J Alderdice; E M Whitehead
Journal:  Arthritis Rheum       Date:  2003-08-15

3.  Lung injury linked to etanercept therapy.

Authors:  Laura Peno-Green; Geronomo Lluberas; Thomas Kingsley; Steven Brantley
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

4.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321
  4 in total
  20 in total

Review 1.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

Review 2.  Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.

Authors:  Y Allanore; G Devos-François; C Caramella; P Boumier; V Jounieaux; A Kahan
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

Review 3.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 4.  Interstitial lung disease: progress and problems.

Authors:  S J Bourke
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

5.  Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.

Authors:  Elizabeth F Redente; Rebecca C Keith; William Janssen; Peter M Henson; Luis A Ortiz; Gregory P Downey; Donna L Bratton; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

6.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

7.  Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats.

Authors:  Nejat Altintas; Mustafa Erboga; Cevat Aktas; Bulent Bilir; Murat Aydin; Aysun Sengul; Zehra Ates; Birol Topcu; Ahmet Gurel
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

8.  Bronchospasm associated with anti-TNF treatment.

Authors:  S Dubey; N Kerrigan; K Mills; D G Scott
Journal:  Clin Rheumatol       Date:  2009-04-02       Impact factor: 2.980

Review 9.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

10.  Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases.

Authors:  Seung Taek Song; Song Soo Kim; Ji Young Kim; So Young Lee; Kwangwoo Kim; In Sun Kwon; Ji Na Kim; Won Hong Park; In Seol Yoo; Su-Jin Yoo; Jin Hyun Kim; Seong Wook Kang; Seung-Cheol Shim
Journal:  Lung       Date:  2016-07-02       Impact factor: 2.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.